Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera Therapeutics in $584.5 Million Deal
核心洞察
Foresee Pharmaceuticals (搜索) has signed an exclusive global licensing agreement with Primevera Therapeutics (搜索) for its MMP-12 (搜索) inhibitor programs, including FP-025, FP-020, and third-generation compounds in discovery.
The deal includes a $10 million upfront payment, potential milestones up to $584.5 million, single-digit royalties, and Foresee retains 19% equity in Primevera.
Primevera will advance FP-020 toward Phase II trials in asthma (搜索) with FDA submission expected in early 2026, while FP-025 prepares for rare disease indications.
Foresee Pharmaceuticals (搜索) has entered into a transformative licensing agreement with Primevera Therapeutics (搜索), transferring exclusive global rights to its matrix metalloproteinase-12 (MMP-12 (搜索)) inhibitor portfolio in a deal valued at up to $584.5 million. The agreement, announced following approval at Foresee's 2025 Extraordinary General Shareholders' Meeting, includes the company's lead MMP-12 compounds FP-025, FP-020, and third-generation inhibitors currently in drug discovery.
Under the terms of the agreement, Foresee USA will receive a $10 million upfront payment, potential development and commercial milestones totaling $574.5 million, and tiered single-digit percentage royalties on future sales. Additionally, Foresee will maintain a 19% equity stake in Primevera, ensuring continued participation in the program's value creation. Should Primevera sublicense its rights, Foresee will receive a tiered percentage of sublicense proceeds in lieu of milestones and royalties.
Strategic Focus on Core Assets
The licensing deal represents a strategic pivot for the Taiwan and US-based biopharmaceutical company, allowing it to concentrate resources on its Stabilized Injectable Formulation (SIF) technology and CAMCEVI franchise. Dr. Ben Chien, Foresee's Chairman and CEO, stated that "over the past decade Foresee has shown unwavering commitment to the discovery and development of MMP-12 (搜索) inhibitors, which has allowed us to become recognized globally as a leader in this space. Our partnership with Primevera allows us to continue this mission in a more focused and streamlined way while we foster Foresee's path to profitability."
The transaction is expected to have a positive material impact on Foresee's working capital and shareholder equity while reducing R&D expenses and reinforcing financial stability. The company plans to focus on near to mid-term profitability by prioritizing CAMCEVI and its FP-001 six-month long-acting injectable, which recently completed a successful pivotal Phase 3 study in central precocious puberty (搜索) patients with NDA submission targeted for 2026.
MMP-12 Development Programs
Going forward, Primevera will assume all subsequent development costs for the MMP-12 (搜索) inhibitor programs. The development strategy focuses on two key compounds:
FP-020 (Linvemastat): This follow-on oral MMP-12 (搜索) inhibitor has completed Phase 1 studies in healthy volunteers and is being prepared for an Investigational New Drug (IND) application for Phase II clinical trials in asthma (搜索). The FDA submission is expected in early 2026, with development targeted for severe asthma and chronic obstructive pulmonary disease (COPD (搜索)).
FP-025 (Aderamastat): The highly selective oral MMP-12 (搜索) inhibitor targeting inflammatory and fibrotic diseases successfully completed a Phase 2 proof-of-concept study in allergic asthmatic patients. Primevera is preparing for future Phase II clinical trials in rare disease indications, with development focused on rare immune-fibrotic diseases including cardiac sarcoidosis (搜索).
CAMCEVI Portfolio Expansion
While divesting its MMP-12 (搜索) assets, Foresee continues to build its revenue stream through CAMCEVI, its approved treatment for advanced prostate cancer (搜索). CAMCEVI 42 mg is currently approved in the U.S., Canada, EU, Taiwan, Israel, and the UK, having launched in the U.S. in April 2022. The company received FDA approval for CAMCEVI ETM on August 25, 2025, while EU regulatory review for the three-month version remains ongoing.
The CAMCEVI six-month formulation has demonstrated stable sales in the U.S., and the three-month formulation, which holds broader commercial potential, is expected to launch in Q4 2026. Beyond prostate cancer, the six-month LAI formulation is being developed for central precocious puberty (搜索) through the ongoing Casppian Phase 3 clinical study, and in a Phase 3 trial for premenopausal breast cancer (搜索) in China through a partnership.
The licensing agreement positions both companies to maximize their respective strengths, with Foresee focusing on its proven SIF technology platform while Primevera advances the MMP-12 (搜索) inhibitor portfolio toward potential regulatory approvals in respiratory and rare diseases.